US FDA approves Salix's Xifaxan for hepatic encephalopathy
This article was originally published in Scrip
Executive Summary
The US FDA has approved Salix Pharmaceuticals' antibiotic Xifaxan (rifaxamin) for the treatment of overt hepatic encephalopathy in patients with advanced liver disease.